EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieÄquivalenzstudie

Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared to the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial

Kirstine Nørregaard Hansen iD, Lisette Okkels Jensen iD, Michael Maeng iD, Martin Kirk Christensen iD, Manijeh Noori iD, Johnny Kahlert, Lars Jakobsen iD, Anders Junker, Phillip Freeman, Julia Ellert-Gregersen, Bent Raungaard, Christian Juhl Terkelsen und 2 weitere

Circulation: Cardiovascular Interventions · 2023

DOI: 10.1161/circinterventions.122.012332 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2023. Verfasst von Kirstine Nørregaard Hansen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Odense University Hospital, Denmark (K.N.H., L.O.J., M.N., A.J., J.E.-G., K.T.V.). Hauptthemen laut MEDLINE: Coronary Artery Disease, Drug-Eluting Stents, Myocardial Infarction, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biodegradable polymer drug-eluting stents were developed to improve safety and efficacy outcomes for patients undergoing percutaneous coronary intervention. However, few long-term follow-up efficacy studies are available. The study sought to investigate 5-year results from the SORT OUT VII trial (Scandinavian Organization for Randomized Trials With Clinical Outcome) comparing the biodegradable polymer ultrathin-strut sirolimus-eluting Orsiro stent (O-SES) versus the biodegradable polymer biolimus-eluting Nobori stent (N-BES).

Methods

This registry-based, randomized, multicenter, single-blinded, noninferiority trial compared O-SES and N-BES in an all-comer population. The composite primary end point, target lesion failure, consisted of cardiac death, myocardial infarction related to the target lesion, or target lesion revascularization within 1 year. Follow-up was extended to 5 years.

Results

Five-year follow-up was completed for 2521 patients (99.8%). Five-year target lesion failure did not differ between O-SES (12.4%) and N-BES (13.1%; rate ratio [RR], 0.94 [95% CI, 0.75–1.18]). Cardiac death (RR, 0.95 [95% CI, 0.67–1.34]), target myocardial infarction (RR, 1.14 [95% CI, 0.76–1.71]), target lesion revascularization (RR, 0.90 [95% CI, 0.67–1.21]), and definite stent thrombosis rates (RR, 0.73 [95% CI, 0.41–1.33]) did not differ significantly between the 2 stents. Within the first year, definite ST was significantly lower for O-SES (0.4%) compared to N-BES (1.2%; RR, 0.33 [95% CI, 0.12–0.92]), but no difference was from 1 through 5 years: O-SES 1.2% and N-BES 0.9% (RR, 1.28 [95% CI, 0.58–2.82]).

Conclusions

Five years after treatment with biodegradable polymer stents, target lesion failure did not differ among O-SES and N-BES. Definite stent thrombosis was less often seen within the first year in the O-SES but the difference was not maintained after 5 years. Registration: URL: https://clinicaltrials.gov ; Unique identifier: NCT01879358.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseDrug-Eluting StentsMyocardial InfarctionPercutaneous Coronary InterventionHumansSirolimusRisk FactorsTreatment OutcomeAbsorbable ImplantsPolymersProsthesis DesignAlkanesulfonic Acids

Stichwörter der Autor:innen

drug-eluting stentpercutaneous coronary interventionsafety

Substanzen

SirolimusPolymersBESAlkanesulfonic Acids

Autor:innen und Institutionen

  • Department of Cardiology, Odense University Hospital, Denmark (K.N.H., L.O.J., M.N., A.J., J.E.-G., K.T.V.).
  • Department of Cardiology, Aarhus University Hospital, Denmark (M.M., L.J., C.J.T., E.H.C.).
  • Department of Cardiology, Aalborg University Hospital, Denmark (M.K.C., P.F., B.R.).
  • Department of Clinical Epidemiology, Aarhus University Hospital, Denmark (J.K.).

ORCID-Profile: Kirstine Nørregaard Hansen, Lisette Okkels Jensen, Michael Maeng, Martin Kirk Christensen, Manijeh Noori, Lars Jakobsen

Zitieren

APA

Hansen, K. N., Jensen, L. O., Maeng, M., Christensen, M. K., Noori, M., Kahlert, J., Jakobsen, L., Junker, A., Freeman, P., Ellert-Gregersen, J., Raungaard, B., Terkelsen, C. J., Veien, K. T., & Christiansen, E. H. (2023). Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared to the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.122.012332

Vancouver

Hansen KN, Jensen LO, Maeng M, Christensen MK, Noori M, Kahlert J, et al. Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared to the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial. Circulation: Cardiovascular Interventions. 2023. doi:10.1161/circinterventions.122.012332

BibTeX
@article{Hansen2023,
  author = {Hansen, Kirstine Nørregaard and Jensen, Lisette Okkels and Maeng, Michael and Christensen, Martin Kirk and Noori, Manijeh and Kahlert, Johnny and Jakobsen, Lars and Junker, Anders and Freeman, Phillip and Ellert-Gregersen, Julia and Raungaard, Bent and Terkelsen, Christian Juhl and Veien, Karsten Tange and Christiansen, Evald Høj},
  title = {Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared to the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2023},
  doi = {10.1161/circinterventions.122.012332}
}
Kostenlos starten →